The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1475
Lenvatinib (Lenvima) for Thyroid Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the oral multikinase inhibitor lenvatinib (Lenvima – Eisai) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular) refractory to radioactive iodine treatment.

STANDARD TREATMENT — Surgery and radioactive iodine are the preferred treatments for differentiated thyroid cancer. Cytotoxic agents such as doxorubicin have not been shown to improve survival. Recently, use of tyrosine kinase inhibitors has shown promising results.1 The oral multikinase inhibitor sorafenib (Nexavar), approved by the FDA in 2013 for treatment of locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, has increased progression-free survival by about 5 months compared to placebo.2 In a small preliminary trial, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lenvatinib (Lenvima) for Thyroid Cancer (online only)
Article code: 1475f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian